HDAX Therapeutics

HDAX Therapeutics is a private pharmaceutical company dedicated to developing first-in-class small molecule therapeutic drugs for neurological and cardiac indications caused by microtubule dysfunction. HDAX's drug discovery platform focuses on HDAC6, a relevant target for disease modification in chemotherapy-induced peripheral neuropathy (CIPN) and other neuropathies and neurodegenerative diseases, with the potential to become a first-in-class treatment.